A brief report sets forth a “new normal,” lets NCI start to streamline clinical trials November 11, 2022Vol.48 No.41By Paul Goldberg
Trials & Tribulations All colorectal cancer patients require germline testing at diagnosis and somatic testing at advanced disease diagnosis July 15, 2022Vol.48 No.28By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Trials & Tribulations Burnout from the elusive quest for quality July 15, 2022Vol.48 No.28By Banu E. Symington
Trials & Tribulations Transforming the future of radiation oncology:Three ways collaboration accelerates FLASH radiation therapy research June 24, 2022Vol.48 No.25By Karen J. Kirkby
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab June 10, 2022Vol.48 No.23By Alice Tracey
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
Trials & Tribulations Here’s how we can make clinical trials more inclusive February 11, 2022Vol.48 No.06By Jenny Sherak
Trials & Tribulations Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment February 04, 2022Vol.48 No.05By Gustaf Salford
